Fascaplysin sensitizes cells to TRAIL-induced apoptosis through upregulating DR5 expression

Chinese Journal of Oceanology and Limnology

Volumn 31, Issue 3, 2013, Pages 560-569

  Wang, Feng ^a   Chen, Haimin ^b   Yan, Xiaojun ^b   Zheng, Yanling ^b  

^a Lihuili Hospital of Ningbo Medical Center   (China)

^b NINGBO UNIVERSITY   (China)

Author keywords

apoptosis; DR5; fascaplysin; microarray; TRAIL

Indexed keywords

EID: 84877320335     PISSN: 02544059     EISSN: 19935005     Source Type: Journal    
DOI: 10.1007/s00343-013-2215-y     Document Type: Article

References (23)

1. Bradford M A. 1976. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254.
2. Brazma A, Hingamp P, Quackenbush J, Shelock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball C, Causton H C, Kim I F, Markowitz V, Matese J C, Parkinson H, Robinson A, Sarkans U, Schulze-kremer S, Stewart J, Taylor R, Vilo J, Vingron M. 2001. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet., 29: 365-371.
3. Calbo J, Serna C, Garriga J, Grana X, Mazo A. 2004. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity. Cell Death Differ., 11: 1 055-1 065.
4. Compagno M, Lim W K, Grunn A, Nandula S V, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L. 2009. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature, 459: 717-721.
5. Griffith T S, Chin W A, Jackson G C, Lynch D H, Kubin M Z. 1998. Intercellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol., 161: 2 833-2 840.
6. Guo Y, Guo H, Zhang L, Xie H, Zhao X, Wang F, Li Z, Wang Y, Ma S, Tao J, Wang W, Zhou Y, Yang W, Cheng J. 2005. Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBVproducing cells. J. Virol., 79: 14 392-14 403.
7. Hormann A, Chaudhuri B, Fretz H. 2001. DNA binding properties of the marine sponge pigment fascaplysin. Bioorg. Med. Chem., 9: 917-921.
8. Jiminez C, Quinoa E, Adamczeski M, Hunter L M, Crews P. 1991. Novel sponge-derived amino acids. 12 Tryptophanderived pigments and accompanying sesterpenes from Fascaplysinopsis reticulate. J. Org. Chem., 56: 3 403-3 410.
9. Jin S, Tong T, Fan W, Fan F, Antinore M J, Zhu X, Mazzacurati L, Li X, Petrik K L, Rajasekaran B, Wu M, Zhan Q. 2002. GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. Oncogene, 21: 8 696-8 704.
10. LeBlanc H N, Ashkenazi A. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ., 10: 66-75.
11. Liebermann D A, Hoffman B. 2007. Gadd45 in the response of hematopoietic cells to genotoxic stress. Blood Cell Mol. Dis., 39: 329-335.
12. Lin J, Yan X J, Chen H M. 2007. Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo. Cancer Chemother. Pharmacol., 59: 439-445.
13. Lu X L, Zheng Y L, Chen H M, Yan X J, Wang F, Xu W F. 2009. Anti-proliferation of human cervical cancer HeLa cell line by fascaplysin through apoptosis induction. Acta Pharm. Sinica, 44: 980-986. (in Chinese with English abstract).
14. Popov A M, Stonik V A. 1991. Physiological activity of fascaplisine-an unusual pigment from tropical sea fishes. Antibiot. Khimioter., 36: 12-14.
15. Roll D M, Ireland C M, Lu H S M, Clardy J. 1988. Fascaplysin, an unusual antimicrobial pigment from the marine sponge Fascaplysinopsis sp. J. Org. Chem., 53: 3 276-3 278.
16. Schmitz N M R, Hirt A, Aebi M, Leibundgut K. 2006. Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia. Am. J. Pathol., 169: 1 074-1 079.
17. Segraves N L, Robinson S J, Garcia D, Said S A, Fu X, Schmitz F J, Pietraszkiewicz H, Valeriote F A, Crews P. 2004. Comparison of fascaplysin and related alkaloids: a study of structures, cytotoxicities, and sources. J. Nat. Prod., 67: 783-792.
18. Shapiro G I. 2006. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol., 24: 1 770-1 783.
19. Soni R, Muller L, Furet P, Schoepfer J, Stephan C, Zumstein-Mecker S, Fretz H, Chaudhuri B. 2000. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun., 275: 877-884.
20. Subramanian B, Nakeff A, Tenney K, Crews P, Gunatilaka L, Valeriote F. 2006. A new paradigm for the development of anticancer agents from natural products. J. Exp. Ther. Oncol., 5: 195-204.
21. Tarragona J, Llecha N, Santacana M, Lopez S, Gatius S, Llobet D, Dolcet X, Palomar-Asenjo V, Gonzalez-Tallada F J, Matias-Guiu X. 2010. DcR1 expression in endometrial carcinomas. Virchows. Arch., 456: 39-44.
22. Wu G S. 2009. TRAIL as a target in anti-cancer therapy. Cancer Lett., 285: 1-5.
23. Zheng Y L, Lu X L, Lin J, Chen H M, Yan X J, Wang F, Xu W F. 2010. Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity. Biomed. Pharmacother., 64: 527-533.